ArticleOncology letters2019
High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Survival and Clinicopathological Significance of CD47 in Human Solid Tumors: An Updated Systematic Reviews and Meta-Analysis.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- In Vivo Immunoscoring Technique to Monitor Anti-CD47 Immunotherapy Efficacy in Triple-Negative Breast Cancer.Cancer medicine · 2026Article
- CD47 promotes mitogen-activated protein kinase and epithelial-to-mesenchymal transition molecular programs to drive prometastatic phenotypes in non-small cell lung cancer.Molecular oncology · 2026Article
- Inhibition of histone demethylase LSD1 suppresses CD47 expression and enhances efficacy of CD47 blockade in breast cancer.Journal for immunotherapy of cancer · 2026Article
- Podophyllotoxin sensitizes triple-negative breast cancer cells to CD47-targeted immunotherapy.Cell insight · 2026Article
- Tumor-associated protease-activated anti-CD47 antibody precisely maintains phagocytic ability of macrophages with minimal effect on healthy tissue.Journal of translational medicine · 2026Article
- Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancer.bioRxiv : the preprint server for biology · 2026Article
- Low-dose DOX-polygodial nanosystem modulates the CD47/CALR axis for safer triple negative breast cancer treatment.Nanoscale advances · 2026Article
- Article
- BET bromodomain inhibition potentiates antitumor activity of tumor-associated macrophages and enhances anti-CD47 immunotherapy in triple-negative breast cancer.Apoptosis : an international journal on programmed cell death · 2026Article
- Expression of cluster of differentiation 47 (CD47) and signal regulatory protein alpha (SIRPα) as prognostic biomarkers and potentially therapeutic targets in esophageal squamous cell carcinoma.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Targeting the CD47-SIRPalpha checkpoint in multiple myeloma.Discover oncology · 2025Review
- PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47/SHP2/SIRPα/SYK/FcγR signalings in tumor associated macrophages.Scientific reports · 2025Article
- Roles of tumor-associated macrophages in triple-negative breast cancer progression.Frontiers in immunology · 2025Review
- CD47 expression in solid tumors correlates with phagocytic tumor-associated macrophage gene signature.Frontiers in immunology · 2025Article
- Integrated Analysis of Phagocytic and Immunomodulatory Markers in Cervical Cancer Reveals Constellations of Potential Prognostic Relevance.International journal of molecular sciences · 2024Article
- Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles.Acta pharmaceutica Sinica. B · 2024Article
- Immunohistochemical Expression of CD47 and CD68 in Breast Carcinoma and Their Prognostic Value.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion.Biology · 2024Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD47 functions as a dominant anti-engulfment signal on tumour cells and is overexpressed in various malignant tumours. However, the expression and functional significance of CD47 in triple-negative breast cancer (TNBC) is not completely understood. In the present study, CD47 was demonstrated to be overexpressed in TNBC solid tumours. Moreover, increased CD47 expression was significantly associated with an advanced tumour-node-metastasis stage, lymph node involvement and recurrence. Moreover, CD47 was an unfavourable and independent prognostic factor for 5-year disease-free survival in patients with TNBC. In addition, the expression of CD47 was associated with several markers of epithelial-mesenchymal transition (EMT). The present study was the first to demonstrate an association between increased expression of CD47 with EMT and poor prognosis of TNBC. Thus, CD47 may be a potential prognostic biomarker and therapeutic target for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.